T细胞/PD-1/PD-L1通路在动脉粥样硬化免疫调控中的作用

Role of T Cell/PD-1/PD-L1 Pathway in Immunomodulation of Atherosclerosis

程序性细胞死亡受体1(PD-1)/程序性细胞死亡配体1(PD-L1)通路是临床免疫检查点抑制剂治疗肿瘤的靶点,主要与肿瘤、感染及一些自身免疫性疾病相关。近年来,PD-1/PD-L1通路在动脉粥样硬化(As)中的作用受到关注。T细胞是参与As最重要的免疫细胞之一,T细胞上的PD-1与其配体PD-L1结合调控As中T细胞的免疫反应,但具体的免疫调控机制仍不全面。PD-1/PD-L1可能是治疗As新的研究方向,故需阐明T细胞/PD-1/PD-L1通路在As免疫调控中的作用机制,并防治目前PD-1/PD-L1免疫检查点抑制剂治疗肿瘤过程中引发的心血管不良事件。

Programmed cell death protein 1(PD-1)/programmed cell death-ligand 1(PD-L1)pathway is the target for clinical immune checkpoint inhibitors treatment of tumors,which is mainly related to tumors,infections and some autoimmune diseases.In recent years,the role of PD-1/PD-L1 in atherosclerosis(As)has received close attention.T cells are one of the most important immune cells involved in As,and binding of PD-1 on T cells and PD-L1 can modulate the immune response of T cells in As,but the specific immunomodulation mechanisms are still incomplete.PD-1/PD-L1 may represent a new direction for future research in the treatment of As.Therefore,it is necessary to elucidate the immunomodulation mechanisms of T cell/PD-1/PD-L1 pathway in As,and to prevent and treat existing adverse cardiovascular events caused by PD-1/PD-L1 immune checkpoint inhibitors treatment of tumors.